<div id="readability-page-1"><p>Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Analysts at HC Wainwright lifted their FY2028 earnings per share estimates for shares of Fulcrum Therapeutics in a research report issued on Monday, December 8th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of $0.94 for the year, up from their previous forecast of $0.45. HC Wainwright has a &#34;Buy&#34; rating and a $25.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics' FY2029 earnings at $1.91 EPS.</p><div><p><span></span><span>Get <strong>Fulcrum Therapeutics</strong> alerts:</span></p></div><p>Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.02). </p><p>Other research analysts also recently issued reports about the stock. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada boosted their target price on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a &#34;sector perform&#34; rating in a research note on Monday. Stifel Nicolaus  set a $25.00 target price on Fulcrum Therapeutics in a research report on Monday. Truist Financial  set a $14.00 price target on Fulcrum Therapeutics in a report on Monday, November 24th. Finally, Citigroup  reissued an &#34;underperform&#34; rating on shares of Fulcrum Therapeutics in a research report on Monday. One research analyst  has rated the stock with a Strong Buy rating, six have issued  a Buy rating, one  has assigned  a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company  has an average rating of &#34;Hold&#34; and a consensus target price of $18.50.</p><p><b>Check Out Our Latest Research Report on Fulcrum Therapeutics</b></p><h2>Fulcrum Therapeutics Stock Performance</h2><p>Shares of NASDAQ FULC opened at $14.60 on Wednesday. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $15.74. The firm has a market cap of $790.12 million, a P/E ratio of -12.37 and a beta of 3.17. The stock has a fifty day moving average price of $9.56 and a two-hundred day moving average price of $7.99. </p><h2>Hedge Funds Weigh In On Fulcrum Therapeutics</h2><p>Several large investors have recently added to or reduced their stakes in FULC. Jump Financial LLC bought a new stake in  Fulcrum Therapeutics in the 1st quarter valued at $30,000.  Brooklyn Investment Group lifted its holdings in shares of  Fulcrum Therapeutics by 209.7% during the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock worth $35,000 after acquiring an additional 8,254 shares during the period.  Quarry LP acquired a new stake in shares of  Fulcrum Therapeutics during the 3rd quarter valued at about $35,000.  Virtu Financial LLC bought a new stake in  Fulcrum Therapeutics in the first quarter valued at about $39,000.  Finally, Russell Investments Group Ltd. raised its position in  Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company's stock worth $64,000 after purchasing an additional 9,092 shares in the last quarter. Institutional investors and hedge funds own  89.83% of the company's stock. </p><h2>Insider Buying and Selling</h2><p>In other news, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $11.03, for a total value of $165,450.00. Following the transaction, the director directly owned 484,864 shares in the company, valued at approximately $5,348,049.92. The trade was a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.00% of the stock is owned by company insiders. </p><h2>About Fulcrum Therapeutics</h2> (Get Free Report)<p>Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Fulcrum Therapeutics</li><li>Options Trading - Understanding  Strike Price</li><li>Insiders Are Selling These 3 Stocks—Here’s Why</li><li>What Are Earnings Reports?</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>What is a support level?</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlVMQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlVMQw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Fulcrum Therapeutics Right Now?</h2><p>Before you consider Fulcrum Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulcrum Therapeutics wasn't on the list.</p><p>While Fulcrum Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

FULC

<p>HC Wainwright analysts raised their FY2028 earnings per share estimate for Fulcrum Therapeutics from $0.45 to $0.94 and set a $25.00 price target with a 'Buy' rating. The consensus estimate for the current full-year earnings is ($0.16) per share. Other analysts have mixed ratings, with an average rating of 'Hold' and a consensus target price of $18.50.</p>

What is HC Wainwright's Forecast for FULC FY2028 Earnings?